Abstract
Advanced heart failure is now one of the major causes of death worldwide, with a reputation for impairment, morbidity, and suffering before the terminal event. Most patients with ventricular dysfunction and heart failure eventually move into more advanced stages of the condition despite the best efforts of physicians and optimal use of available drugs. The development of calcium-sensitizing agents represents a recent pharmaceutical initiative to enlarge the therapeutic armamentarium for patients whose condition and symptoms are not adequately controlled by existing means. The potential role of this drug group in the treatment of advanced heart failure is discussed.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
